| chlorthalidone / Generic mfg. |
2012-004704-35: Comparison of two drugs against high blood pressure in dermatology patients. Vergelijking van twee medicijnen tegen hoge bloeddruk bij dermatologie patiënten. |
|
|
| Ongoing | 4 | 15 | Europe | Amlodipine, Chlorthalidon, Chlorthalidone, | | Hypertension, induced by the use of a Calcineurin Inhibitor (CNI) Hypertensie, geïnduceerd door het gebruik van een Calcineurine Remmer (CNI) | | | | |
| Withdrawn | 4 | 15 | US | Amlodipine Besylate, Chlorthalidone | Northwestern University, National Heart, Lung, and Blood Institute (NHLBI), American Society for Transplantation | High Blood Pressure, Liver Transplant, Renal Function Abnormal | 10/23 | 10/23 | | |
| Suspended | 4 | 34 | Canada | Furosemide, Chlorthalidone | University of Alberta | End Stage Renal Disease on Dialysis | 02/25 | 02/25 | | |
DECONGEST, NCT05411991: Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment |
|
|
| Recruiting | 4 | 104 | Europe | UNa measurement after intravenous loop diuretic bolus, Intravenous acetazolamide 500 mg OD, Diamox (brand name for acetazolamide), Intravenous bumetanide TID, Burinex (brand name for bumetanide), Oral chlorthalidone OD, Hygroton (brand name for chlorthalidone), Intravenous canrenoate 200 mg OD, Soldactone (brand name for canrenoate), Maintenance infusion, Oral potassium supplements, KCl, Intravenous hypertonic saline, Switch to oral diuretic therapy, Usual AHF care | Vrije Universiteit Brussel, Roche Diagnostics, Jessa Hospital | Acute Heart Failure, Diuretics Drug Reactions | 03/24 | 04/24 | | |
| Recruiting | 4 | 46 | US | Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide) | VA Office of Research and Development | Chronic Kidney Disease, Hypertension | 07/25 | 07/25 | | |
NCT06041529: Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension |
|
|
| Not yet recruiting | 4 | 250 | RoW | Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Truset 40/5/12.5mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg, Twynsta 40/5 mg, Dichlozid 25 mg | Yuhan Corporation | Essential Hypertension | 02/25 | 06/25 | | |
NCT04519164: Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity |
|
|
| Recruiting | 4 | 80 | US | Eplerenone, Inspra, Chlorthalidone with potassium chloride, hygroton | Brigham and Women's Hospital | Metabolic Syndrome, Hypertension, Overweight and Obesity | 11/25 | 11/25 | | |
NCT05593055: Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension |
|
|
| Recruiting | 4 | 75 | US | Eplerenone, Chlorthalidone, Potassium | Brigham and Women's Hospital | Hypertension, Left Ventricular Hypertrophy | 09/26 | 12/26 | | |
OPTION TREAT, NCT05920005: Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension |
|
|
| Recruiting | 3 | 698 | RoW | candesartan cilexetil + chlorthalidone + amlodipine, Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg) | Hospital Israelita Albert Einstein, Libbs Farmacêutica LTDA | Hypertension | 12/23 | 07/24 | | |
NCT02493322: Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control |
|
|
| Not yet recruiting | 3 | 261 | NA | Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg, Olmesartan medoxomil 20mg + Chlortalidone 25mg, Olmesartan 20mg + hydrochlorothiazide 12,5mg, Benicar HCT® | EMS | Essential Arterial Hypertension | 06/26 | 11/26 | | |
NCT02483936: Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control |
|
|
| Not yet recruiting | 3 | 348 | NA | Olmesartan medoxomil 40mg + chlorthalidone 12,5mg, Olmesartan medoxomil 40mg + chlorthalidone 25mg, Olmesartan 40mg + Hydrochlorothiazide 12,5mg, Benicar HCT, Olmesartan 40mg + Hydrochlorothiazide 25mg | EMS | Arterial Hypertension | 06/25 | 09/26 | | |
NCT05580510: " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD " |
|
|
| Not yet recruiting | 2/3 | 160 | RoW | Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID, Entresto, Empagliflozin 10 MG OD, Jardiance | Instituto Nacional de Cardiologia Ignacio Chavez, Boehringer Ingelheim laboratory | Congenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection Fraction | 07/23 | 03/24 | | |
| Completed | 2 | 160 | US | Chlorthalidone, Placebo | Indiana University | Renal Insufficiency, Chronic, Hypertension | 04/21 | 04/21 | | |
| Recruiting | 2 | 24 | US | Spironolactone, Chlorthalidone, Placebo | Indiana Institute for Medical Research | Renal Insufficiency, Chronic Hypertension | 12/23 | 12/23 | | |
| Not yet recruiting | 2 | 99 | Europe | Indapamide 2.5 MG, Hydrochlorothiazide 50Mg, Chlorthalidone 25mg | Insel Gruppe AG, University Hospital Bern, University of Bern | Kidney Stone | 06/27 | 06/27 | | |
STU-2024-0140, NCT06287580: Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension. |
|
|
| Not yet recruiting | 1 | 50 | US | chlorthalidone 25 mg, Placebo | University of Texas Southwestern Medical Center | Essential Hypertension, Older Adults | 01/26 | 01/27 | | |
NCT06282549: Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension |
|
|
| Recruiting | N/A | 1210 | RoW | Telmisartan/Amlodipine/Chlorthalidone(Truset) | Yuhan Corporation | Essential Hypertension | 03/27 | 03/27 | | |
NCT02665117: Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate |
|
|
| Completed | N/A | 61 | US | Potassium Magnesium Citrate (KMgCit), KMgCit, Potassium Chloride (KCl), KCl, Chlorthalidone | University of Texas Southwestern Medical Center | Hypertension | 11/22 | 11/22 | | |
NCT04470830: A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea |
|
|
| Completed | N/A | 718 | RoW | | Celltrion Pharm, Inc. | Essential Hypertension | 05/23 | 05/23 | | |
| Recruiting | N/A | 208 | US | OPTIMA-BP Intervention | Case Western Reserve University, University Hospitals Cleveland Medical Center | Hypertension, Self-Management, Technology, Quality of Life | 12/25 | 05/26 | | |